Advagene Biopharma Co Ltd

Advagene’s capital structure shows a high price-to-book ratio of 11.57 and a debt-to-equity ratio of 0.03, indicating minimal leverage and strong equity backing. However, the company reported negative operating cash flow of -TWD 63.33 million and free cash flow of -TWD 68.41 million, signaling liquidity constraints despite a current ratio of 13.69. Profitability metrics are negative, with a return on equity of -44.85% and return on assets of -41.01%, far below the industry median for biotechnology firms. The company’s net loss of TWD 68.29 million and operating loss of TWD 70.92 million highlight operational inefficiencies and lack of revenue generation. Geographically, Advagene’s revenue is not disclosed by segment or region, but its operations are based in Taiwan. The company’s product pipeline is concentrated in vaccines, with no diversification into other therapeutic areas or markets. Growth prospects are uncertain, as the company has no reported revenue and faces significant operating losses. Outlook data is not available for future fiscal years, but the absence of revenue and ongoing cash outflows suggest a challenging path to profitability. Risk factors include liquidity pressure from negative operating cash flow and free cash flow, despite a high current ratio. The company has low dilution risk, with no difference between basic and diluted shares outstanding, but its negative net cash position raises concerns about short-term solvency. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the company’s financial snapshot indicates ongoing losses and no revenue, suggesting a need for capital infusions or strategic partnerships to advance its vaccine pipeline.